Two HDs [108 egg infectious doses (EID)] of NDV-vectored COVID-19 vaccine administered intranasally generated serum anti-S1 antibody responses in 11% (one of nine) and CD8+ T cell responses in 44% (four of nine) of naïve participants in a phase 1 study (26). This evidence concerns the gene CD8A and COVID-19.